全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Drug Resistance Mutations and Genetic Diversity in Patients Treated for HIV Type 1 Infection in Rural Care Centers in Togo

DOI: 10.4236/ojmm.2016.63015, PP. 111-115

Keywords: HIV-1, Antiretroviral Treatment, Drug Resistance, Genetic Diversity, Rural, Togo

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: Access to antiretroviral treatment (ART) in resource-limited countries has increased signif-icantly but scaling up ART into rural areas is more recent and information on treatment outcome in rural areas is still very limited. We reported here virological outcome and drug resistance in ART in rural settings in Togo. Methods: HIV-1 infected adults (≥18 years) and infants were enrolled in routine medical visit at 12 on first-line ART in three HIV care centers. Epidemiological and demographic information and data on ART history were collected. Viral load (VL) was determined and genotypic drug resistance testing was performed on all samples with viral load above 1000 copies/ml. Results: 102 adult patients and 27 infants were consecutively enrolled. Virological failure was observed in 28 (21.5%) patients. For 25/28 patients, sequencing was successful and drug resistance mutations were observed in 23 (92%) of them. The global prevalence of drug resistance in the study population was thus at least 17.8% (23/129), with 7 (6.9%) patients infected with HIV strains that are resistant to two of the three first-line antiretroviral (ARVs) drugs and 9 (8.3%) to all three first-line ARVs. As expected, the observed drug resistance mutations were mainly associated with the drugs used in first line regimens, zidovudine, lamivudine and effavirenz/nevirapine but several patients accumulated high numbers of mutations and developed also cross-resistance to abacavir, didanosine or the new non-nucleoside reverse transcriptase inhibitor drugs, like etravirine and rilpivirine. Conclusion: The observations on ART treatment outcome from ART clinics in rural areas are the same as observed in previous observations in Lomé, the capital city. Although access to viral load will improve treatment outcome, better programme management and implementation of actions to improve factors as patient adherence, drugs stock-outs and lost to follow-up are also essential.

References

[1]  Mutevedzi, P.C. and Newell, M.L. (2014) The Changing Face of the HIV Epidemic in Sub-Saharan Africa. Tropical Medicine and International Health, 19, 1015-1028.
http://dx.doi.org/10.1111/tmi.12344
[2]  Aghokeng, A.F., Monleau, M., Eymard-Duvernay, S., Dagnra, A., Dramane, K., Ngo-Giang, N., et al. (2014) Extraordinary Heterogeneity of Virological Outcomes in Patients Receiving Highly Antiretroviral Therapy and Monitored with the World Health Organization Public Health Approach in Sub-Saharan Africa and Southeast Asia. Clinical Infectious Diseases, 58, 99-109.
http://dx.doi.org/10.1093/cid/cit627
[3]  Rusine, J., Asiimwe-Kateera, B., Van de Wijgert, J., Boer, K.R., Mukantwali, E., Karita, E., et al. (2013) Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1) Infected Individuals from Kigali, Rwanda. PLoS One, 8, e64345.
http://dx.doi.org/10.1371/journal.pone.0064345
[4]  Wadonda-Kabondo, N., Hedt, B.L., Van Oosterhout, J.J., Moyo, K., Limbambala, E., Bello, G., et al. (2012) A Retrospective Survey of HIV Drug Resistance among Patients 1 Year after Initiation of Antiretroviral Therapy at 4 Clinics in Malawi. Clinical Infectious Diseases, 54, 355-361.
http://dx.doi.org/10.1093/cid/cis004
[5]  Semwanga, D., Nsubuga, R.N., Mayanja, B.N., Lyagoba, F., Magambo, B., Yirrel, D., et al. (2013) Effect of HIV-1 Subtypes on Disease Progression in Rural Uganda: A Prospective Clinical Cohort Study. PloS One, 8, e71768.
http://dx.doi.org/10.1371/journal.pone.0071768
[6]  Institut national de la statistiqueet des étudeséconomiques et démographiques (2010)
http://www.stat-togo.org/nada/index.php/catalog/2
[7]  UNAIDS Report on Global AIDS (2013)
http://www.unaids.org/fr/dataanalysis/knowyourresponse/countryprogressreports/2014countries
[8]  WHO (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach.
http://www.who.int/hiv/pub/arv/adult2010/en/index.html
[9]  Dagnra, A.Y., Vidal, N., Mensah, A., Patassi, A., Aho, K., Salou, M., et al. (2011) High Prevalence of HIV-1 Drug Resistance among Patients on First-Line Antiretroviral Treatment in Lomé, Togo. Journal of the International AIDS Society, 14, 30.
http://dx.doi.org/10.1186/1758-2652-14-30
[10]  Hamers, R.L., Oyomopito, R., Kityo, C., Phanuphak, P., Siwale, M., Sungkanuparph, S., et al. (2012) Cohort Profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV Drug Resistance in Sub-Saharan Africa and the Asia-Pacific. International Journal of Epidemiology, 41, 43-54.
http://dx.doi.org/10.1093/ije/dyq192
[11]  Barth, R.E., Tempelman, H.A., Moraba, R. and Hoepelman, A.I. (2011) Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. AIDS Research and Treatment, 2011, 43-75.
http://dx.doi.org/10.1155/2011/434375
[12]  Boullé, C., Kouanfack, C., Laborde-Balen, G., Aghokeng, A.F., Boyer, S., Carrieri, M.P., et al. (2013) Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon. Clinical Infectious Diseases, 57, 604-607.
http://dx.doi.org/10.1093/cid/cit323
[13]  Fofana, D.B., Soulié, C., Baldé, A., Lambert-Niclot, S., Sylla, M., Ait-Arkoub, Z., et al. (2014) High Level of HIV-1 Resistance in Patients Failing Long-Term First-Line Antiretroviral Therapy in Mali. Journal of Antimicrobial Chemotherapy, 69, 2531-2535.
http://dx.doi.org/10.1093/jac/dku153
[14]  Fall-Malick, F.Z., Tchiakpe, E., Ould Soufian, E.S., Diop-Ndiaye, H., Mouhamedoune, B.A., Ould Horma, B.A., et al. (2014) Drug Resistance Mutations and Genetic Diversity in Adults Treated for HIV Type 1 Infection in Mauritania. Journal of Medical Virology, 86, 404-410.
http://dx.doi.org/10.1002/jmv.23860
[15]  Wallis, C.L., Aga, E., Ribaudo, H., Saravanan, S., Norton, M., Stevens, W., et al. (2014) Drug Susceptibility and Resistance Mutations after First-Line Failure in Resource Limited Settings. Clinical Infectious Diseases, 59, 706-715.
http://dx.doi.org/10.1093/cid/ciu314
[16]  Yaotsè, D.A., Nicole, V., Roch, N.F., Mireille, P.D., Eric, D. and Martine, P. (2009) Genetic Characterization of HIV-1 Strains in Togo Reveals a High Genetic Complexity and Genotypic Drug-Resistance Mutations in ARV Naive Patients. Infection, Genetics and Evolution, 9, 646-652.
http://dx.doi.org/10.1016/j.meegid.2009.04.002
[17]  Delgado, E., Ampofo, W.K., Sierra, M., Torpey, K., Pérez-Alvarez, L., Bonney, E.Y., et al. (2008) High Prevalence of Unique Recombinant Forms of HIV-1 in Ghana: Molecular Epidemiology from an Antiretroviral Resistance Study. Journal of Acquired Immune Deficiency Syndromes, 48, 599-606.
http://dx.doi.org/10.1097/QAI.0b013e3181806c0e
[18]  Derache, A., Maiga, A.I., Traore, O., Akonde, A., Cisse, M., et al. (2008) Evolution of Genetic Diversity and Drug Resistance Mutations in HIV-1 among Untreated Patients from Mali between 2005 and 2006. Journal of Antimicrobial Chemotherapy, 62, 456-463.
http://dx.doi.org/10.1093/jac/dkn234
[19]  Tebit, D.M., Ganame, J., Sathiandee, K., Nagabila, Y., Coulibaly, B. and Krausslich, H.G. (2006) Diversity of HIV in Rural Burkina Faso. Journal of Acquired Immune Deficiency Syndromes, 43, 144-152.
http://dx.doi.org/10.1097/01.qai.0000228148.40539.d3

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133